380 results about "Viral replication" patented technology

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention relates to the technical field of molecular biology, in particular to a multichannel virus reporting system based on TAT trans-activation. The invention relates to a multichannel virus reporting system based on TAT trans-activation. The multichannel virus reporting system comprises an activated virus and a reporting cell, the activated virus is a human enterovirus A71 for expressing TAT protein; the reporter cells are cells transfected with reporter plasmids; the reporter plasmid comprises an LTR sequence and a plurality of reporter genes which are started to express by the LTR sequence. When the virus is activated to infect the reporter cell, the TAT protein carried by the virus enters the reporter cell to activate the expression of the downstream reporter gene, and the expression level of the reporter gene can reflect the virus replication condition, so that the screening or mechanism research of related antiviral drugs can be realized. According to the technical scheme, the technical problem that the flexibility, stability and high-throughput screening adaptability of a virus reporting system in the prior art are not ideal can be solved, and the virus reporting system has ideal popularization and application prospects.

The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.

The present invention relates to a conjugate for inhibiting viral replication, a preparation method therefor, and use thereof. The conjugate comprises a dimer or trimer of a portion that inhibits influenza virus neuraminidase (e.g. zanamivir, peramivir, oseltamivir, or an analog thereof), the dimer or trimer being conjugated to an Fc domain monomer, an Fc domain, an Fc-binding peptide, an albumin, or an albumin-binding peptide. The conjugate can be used to treat viral infections (e.g., influenza virus infections).

The invention discloses a PDCoV JS2021-LX strain NS6 gene deletion recombinant virus and a construction method thereof, on the basis of PDCoV JS2021-LX strain infectious clone successfully constructed by a BAC system, the upstream and downstream of the NS6 gene are cut by adopting a CRISPR / Cas9 technology, then the original NS6 gene segment is replaced by green fluorescent protein EGFP through a homologous recombination mode, an NS6 gene deletion recombinant plasmid is obtained, and the NS6 gene deletion recombinant virus is constructed. And after the LLC-PK1 cell is transfected, the recombinant virus without the NS6 protein is rescued. The recombinant virus with the PDCoV NS6 gene deleted is successfully rescued, the virus replication level of the recombinant virus and the virus is rescued through in-vivo and in-vitro evaluation, and pig experiment results show that the pathogenicity of the recombinant virus is reduced, and the recombinant virus has the potential of serving as a candidate strain of an attenuated live vaccine.

To disclose modified influenza virus neuraminidases that improve viral replication, thus improving the yield of vaccine viruses.SOLUTION: Expression of such modified neuraminidases by influenza virus stabilizes co-expressed hemagglutinins, ensuring that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.SELECTED DRAWING: None

The invention relates to the technical field of biology, and aims to provide a zinc ion-containing influenza A virus culture medium and a preparation method thereof. The culture medium contains a serum-free cell culture medium, water, a PBS (Phosphate Buffer Solution), bovine serum albumin with the final concentration of 20g / L, TPCK-Trypsin with the final concentration of 2mu g / mL and zinc ions with the final concentration of 0.009-0.015 mmol / L. According to the invention, zinc ions which are originally considered to generate a virus inhibition effect under a relatively low concentration condition can be used for promoting virus replication after the use concentration range is adjusted; therefore, a brand-new culture medium which can be applied to research on common cell models and virus in-vitro culture models of the influenza A virus is provided, and a new solution is provided for optimizing a vaccine production process. The culture medium is simple in formula and convenient to prepare; all the raw material components are common consumables in laboratories, and the required liquid components can be prefabricated in advance and refrigerated for later use; and large-scale vaccine production can be supported.

The invention belongs to the technical field of medicines, and provides a compound for inhibiting virus replication and application of the compound in preparation of a medicine for resisting feline infectious peritonitis virus (FIPV). The number of the compounds provided by the invention is 10, and the 10 compounds have obvious inhibiting and blocking effects on a 1-bit ribosome frameshift process of the FIPV, and can effectively inhibit the replication and proliferation of the FIPV. The ten compounds can be used for treating and preventing feline infectious peritonitis diseases caused by FIPV infection; the compound disclosed by the invention can be used for preparing anti-FIPV medicines and medicines for treating and preventing feline infectious peritonitis diseases caused by FIPV infection, and has a wide application prospect.

The invention discloses application of a ZNF528 gene as a target spot in preparation of a medicine for inhibiting coronavirus replication, and belongs to the technical field of biological genetic engineering. In order to solve the technical problems of relatively low flexibility, low efficiency and relatively narrow applicability of a traditional host factor in the prior art, the invention provides application of a ZNF528 gene as a target spot in preparation of a medicine for inhibiting coronavirus replication, and a key gene ZNF528 which affects infection and invasion of coronavirus in a human host cell is screened by utilizing a CRISPR (clustered regularly interspaced short palindromic repeats) screening technology; the ZNF528 gene expression inhibitor provided by the invention can be applied to preparation of a coronavirus replication inhibitor; the ZNF528 gene expression synergist provided by the invention can be applied to preparation of a coronavirus replication synergist or a vaccine production synergist.

The invention provides a co-culture system of human alveolar epithelial cells and endothelial cells, which is used for researching interaction in an epithelial-endothelial barrier in lungs. It is indicated that infection with the highly pathogenic influenza A virus A / HK / 483 / 97 (H5N1) can significantly reduce alveolar fluid clearance (AFC) and increase protein permeability (APP). Administration of therapeutic extracellular vesicles (EV) after infection effectively restores AFC and APP, reduces viral replication, and enhances expression of antiviral genes. According to the invention, the treatment potential of EV is highlighted, and a valuable tool is provided for researching acute lung injury and improving a lung drug delivery technology.

The invention belongs to the technical field of biological pharmacy, and particularly relates to an anti-coronavirus medicine and application. According to the application disclosed by the embodiment of the invention, experiments prove that the punicalagin and the punicalagin respectively have strong binding force to SARS-CoV-2 main protease Mpro and have a remarkable inhibition effect on SARS-CoV-2 virus replication, so that the punicalagin and the punicalagin can be used as novel SARS-CoV-2 inhibitors. Therefore, punicalagin and / or punicalagin can be used for preparing products for inhibiting novel coronavirus.

The invention provides application of an IFI16 gene overexpression biological material in preparation of an anti-dengue virus drug, and belongs to the technical field of anti-dengue virus. According to the invention, differentially expressed genes after host cells transfect viruses are found, and the differentially expressed genes are analyzed, so that the key genes related to dengue virus resistance are determined; it is determined that the over-expressed IFI16 gene has the effect of inhibiting dengue virus replication and can be used for preparing the anti-dengue virus medicine.

This article provides a combination of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.

The invention belongs to the technical field of medicines, and discloses application of a compound in prevention and treatment of coronavirus infection and / or diseases caused by coronavirus. In particular discloses application of one or more of G96-69, G96-70, G102-35, G110-74, G115-49 and G118-1 in prevention and treatment of coronavirus infection and diseases caused by the coronavirus, improvement of symptoms caused by the coronavirus and in-vitro inhibition of coronavirus replication in a non-treatment destination, and the G96-69, the G96-70, the G102-35, the G110-74, the G115-49 and the G118-1 have relatively good effects in the aspect of resisting the coronavirus. EC50 for inhibiting mouse hepatitis virus MHV is less than 6 [mu] M; the EC 50 of the HCoV-OC43, the EC 50 of the HCoV-229E and the EC 50 of the HCoV-NL63 which are inhibited by the G96-69 and the G96-70 are all smaller than 2 [mu] M.

The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-COV-2, influenza and HIV / AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

This invention generally relates to a novel RNA / mRNA production and amplification method using viral RNA replicase and / or RNA-dependent RNA polymerase (RdRp) enzymes as well as the associated mRNAs thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA / mRNA sequences carrying at least an RdRp-binding site in the 5′- or 3′-end, or both. The RNA / mRNA so obtained is useful for not only producing mRNA vaccines and / or RNA-based medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase-mediated RNA / mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and / or bacteriophage RNA-dependent RNA polymerases (RdRp), particularly coronaviral and hepatitis C viral (HCV) RdRp enzymes.

The present invention pertains to the use of a vaccine based on an alphavirus RNA replicon particle (αRP) vector encoding an antigen of an IAV-S for the passive vaccination of piglets against a pathogenic infection with swine influenza virus.

The invention belongs to the technical field of agricultural biology, and particularly relates to application of 4 mu 8C in preparation of a medicine for preventing and treating bombyx mori nuclear polyhedrosis virus. Bioinformatics analysis, gene knockout, RT-PCR detection and other modes find that BmIRE1alpha is used as an important molecular target for regulating and controlling bombyx mori nuclear polyhedrosis virus (BmNPV) replication, an inhibitor 4mu8C not only blocks virus replication, but also regulates and controls a bombyx mori endoplasmic reticulum stress pathway and the expression level of key genes, and the BmIRE1alpha can be used for regulating and controlling bombyx mori nuclear polyhedrosis virus (BmNPV) replication. And the cell stress burden caused by virus infection is relieved. Researches show that 4 mu 8C has an accurate and efficient antiviral effect, has more potential compared with traditional pesticides, avoids damage to the environment and non-target organisms, provides new technical support for green and sustainable development of sericulture, and has great development and application prospects.

To provide a method for propagating a recombinant influenza B virus, and a host cell.SOLUTION: A method for propagating a recombinant influenza B virus comprising a mutant BM2 gene having a specific sequence comprises: contacting a host cell with the recombinant influenza B virus; and incubating the host cell for a sufficient time and under conditions suitable for viral replication; where the host cell is an MDCK cell or a Vero cell expressing functional BM2 or chimeric M2-BM2 proteins.SELECTED DRAWING: None

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

This disclosure relates to a method for preparing intermediates useful for preparing compounds that inhibit the function of human immunodeficiency virus (HIV) during the viral replication cycle, such as by disrupting the function of the HIV capsid shell. [Formula 1] JPEG2026524821000058.jpg39145

In order to solve the problem that an efficient and stable anti-plant-virus compound screening and evaluating technology is lacked, the invention provides an efficient anti-plant-virus compound screening and evaluating method based on insect cells. An insect cell line Sf9JSN106 which is obtained through domestication and can maintain infection and replication of plant viruses (representative species: rice stripe viruses) is used for rapidly screening and evaluating the antiviral effect of a compound. Evaluation is carried out from two aspects: 1) evaluating the inhibition effect of the compound on virus replication, wherein the process comprises cell inoculation, virus cell infection, medicament treatment and virus detection; and 2) evaluating the inhibition effect of the compound on virion infection activity, wherein the process comprises cell inoculation, virus treatment by a medicament, cell infection by the virus and virus detection. The method is completed by using a cell culture plate, various compounds can be evaluated at a time, the whole process does not exceed 60 hours, and the method has the characteristics of simplicity, convenience, rapidness and high efficiency, and can be applied to screening evaluation of plant virus resistant compounds and antiviral mechanism research.

The present invention relates to vaccination against animal pathogens using alpha virus-replicon RNA particles and oil adjuvants. To vaccines and kits comprising said replicon particles and said oil adjuvant. The invention also relates to methods and uses for preparing and using the vaccine and the components of the kit.

Methods and compositions are described for modulating the activity of a poxvirus polymerase by modulating the assembly and / or interaction of one or more subunits of the poxvirus polymerase.

The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.

The invention relates to a rep plasmid comprising at least one adeno-associated virus replication protein coding sequence encoding at least one functional rep protein, at least one polyadenylation signal sequence downstream the adeno-associated virus replication protein coding sequence, and a minimal element comprising one or more rep-binding elements downstream the polyadenylation signal sequence. In another aspect, the invention provides a transgene plasmid comprising a CMVie promotor, a transgene, SV40 PolyA, a 5' and a 3' inverted terminal repeats derived from J01901.1 AAV2; wherein the transgene plasmid is selected from one of the following: a conventional single-stranded genome recombinant adeno-associated virus, or a self-complementary genome recombinant adeno-associated virus.

A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

The present invention relates to a circular RNA for targeted inhibition of fish neural necrosis virus replication, as well as a preparation method and application thereof. The circular RNA is NNV-circRNA-1, whose nucleotide sequence is shown in SEQ ID NO:1. The circular RNA is prepared by cyclizing linear NNV-circRNA-1 with T4 RNA ligase 1 and then removing residual linear RNA in the reaction system using RNase R enzyme. The circular RNA prepared by the present invention has good stability and high purity. NNV-circRNA-1 has a strong binding ability with NNV-RdRp protein, can effectively inhibit the replication of NNV virus, and can be used in the preparation of vaccines, antiviral drugs and other biological immune products for fish neural necrosis virus in the field of aquaculture.

The present application relates to viral sensitizers. More specifically, the present application relates to compounds of Formula (I), as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses and increasing transduction.